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Abstract 
The aim of this study was to determine optimal regimes of antibacterial therapy on different stages of acute pancreatitis (AP) 
clinical course and susceptibility of causative agents, which cause AP infectious complications (IC), to antibiotics. 
119 patients with severe and moderate AP were enrolled to the study. The I group was formed from 57 patients (treated during 
2015-2016 years). The II group included 62 patient (treated during 2017-2018 years). Antibiotics from reserve group were used 
for infectious complications’ prophylaxis in the I group. Broad-spectrum antibiotics were administrated in the II group. There 
were no statistically significant difference in the arise of IC (I group – 24,5%; II group – 25,8%; p=1,0). Associations of 
microorganisms were found in 18,5% samples in the I group and 47,4% in the II. There were 23,8% antibiotics with sensitivity 
more then 50% in the I group and 19,2% in the II. 10,0% of IC causative agents produced extended spectrum beta lactamases 
(ESBL) in the I group. In the II group there were 29,6% ESBL-producing microorganisms. 
Causative agents of IC in patients with AP are in majority microorganisms, which are resistant to several antibiotics. This 
characteristic of microorganisms does not depend on type of drug, which is used for prophylactic antibiotic administration 
during early stages of AP clinical course. The increase of ESBL producing bacteria, Gram-negative bacteria and microorganisms’ 
associations among IC causative agents is observed. Administration of antibiotics from reserve group in case of IC occurrence is 
recommended. 
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Introduction Material and Methods 
Acute pancreatitis (AP) is a widespread disease with 
significant social and economical burden. For example, in 
United States AP stands on the third place as a reason for 
hospitalization of patients with digestive tract diseases. 
Number of people who are treated with this diagnosis 
annually exceeds 275 000 persons with financial burden of 
approximately 2,6 billion dollars. Morbidity for AP in US 
ranges from 5 to 30 incidents per 100 000 people and has a 
trend to increase[1,2]. Mortality from AP fluctuates in range 
from 4% to 5% reaching 17-35,2% in case of severe AP with 
infected necrosis and organ failure[3,4]. 
119 patients with severe and moderate AP were enrolled to 
the study. All of them were treated in surgical department 
of Poltava Regional Clinical Hospital named after M.V. 
Sklifosovskiy of Poltava Regional Council during 2013-2018 
years. The group of our patients consisted of 71 men and 48 
women. Mean age of patients was 48,0±14,84 years. 
Formation of groups was made basing of patients` 
treatment time. The I group was formed from 57 patients, 
who were treated during 2013-2014 years. The II group 
included 62 patient, who were treated during 2017-2018 
years. Athlanta classification (2012 revised) was used for 
severity grading of AP[11]. According to current clinical approaches patients with 
mild AP should not be treated with antibiotics. Prescription 
of antibiotics seems reasonable in case of pancreatic and/or 
retroperitoneal tissues necrosis presence to prevent 
purulent complications[5,6]. Nevertheless, it not 
recommended by majority of existing guidelines in the 
beginning of mild or moderate AP[7,8]. Lots of experts 
think, that admission of antibiotic therapy and surgical 
intervention are indicated when the infection of necrotic 
tissues is proven[9]. Furthermore, there is an opinion that 
non-surgical approach can be used in clinically stable 
patients with infected pancreatic necrosis[10]. In any of 
abovementioned situations rational antibacterial therapy 
plays an important role in treatment of patients with AP. 
We analyzed 65 samples (27 in the I group and 38 in the 
II) obtained from patients with IC of AP. In each specimen 
causative agent (or agents) was identified and its antibiotic 
susceptibility was investigated. Considering bacterial 
associations, general data array consisted of 106 distinct 
microbiological isolates (34 in the I group and 72 in the 
second).  
Statistic analysis of obtained data was made using 
STATISTICA 6.0 software system. In particular, two by two 
contingency tables with calculation of Fisher’s exact two-
tailed test and Mann-Whitney U test were used to compute 
the probability of statistically significant difference between 
groups. Probability values were rounded to three decimal 
places. The aim of our study was to determine optimal regimes 
of antibacterial therapy on different stages of AP clinical 
course and susceptibility of causative agents, which cause 
AP infectious complications (IC), to antibiotics. 
 
Results 
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Drugs from reserve group (ertapenem, doripenem, 
meropenem) were prescribed to patients from the I group 
for IC prophylaxis as was established by local treatment 
protocols. Later on suppuration of necrotic tissues or/and 
acute fluid collections was observed in 14 cases (24,5%). 
Approaches to antibiotic prescription were changed in 2016 
and all the patient from the II group were treated with wide 
spectrum drugs (ceftriaxone, ciprofloxacin) for prevention 
of necrotic tissues/acute fluid collections suppuration. IC 
were diagnosed in 16 patients (25,8%) in the II group. There 
were no statistically significant difference between groups 
(p=1,0). 
Acinetobacter spp. 5,9 15,3 0,217 
Alcaligenes spp. 0,0 1,4 1,0 
Nonfermenting Gram-negative bacilli* 2,9 0,0 0,321 
Escherichia coli 11,8 8,3 0,723 
Klebsiella pneumoniae 2,9 25,0 0,006 
Serratia marcescens 0,0 1,4 1,0 
Citrobacter spp. 0,0 2,8 1,0 
Enterobacter spp. 2,9 5,6 1,0 
Candida spp. 0,0 2,8 1,0 
Total 100,0 100,0 - 
Note: *- only group affiliation was identified without further differentiation 
 
The majority of causative agents was represented by 
Gram-negative bacteria in both groups. Nonetheless their 
prevalence raised from 58,8% in the I group to 77,1% in the 
II with trend to statistically significant difference between 
groups (Table 3). 
Only one causative agent was identified in the majority of 
cases (81,5%) in the specimens collected from the patients 
in the I group. The situation with number of causative agent 
in the single sample was different in the II group: only 
52,6% of obtained specimens showed monoculture growth 
and the difference between groups was statistically 
significant for this parameter (p=0,020). Microbial 
associations were detected only in 18,5% from all samples 
in the I group. There also were samples with 4 and 5 
causative agents in the same specimen in the II group, 
albeit such phenomenon wasn’t seen in the I group. 
Percentage of samples with three microorganisms in the II 
group was three times higher than in the I one(Table 1). 
 
Table 3: Some characteristics of IC’s causative agents isolated 
from patients with AP,% 
Characteristic I group II group p 
Gram-positive bacteria 41,2 22,9 
0,066 
Gram-negative bacteria 58,8 77,1 
Nonfermenting Gram-negative bacilli 41,2 31,9 0,388 
ESBL producers 10,0 29,6 0,126 
 
In the same time the incidence of nonfermenting Gram-
negative bacilli decreased (31,9% in the II group and 41,2% 
in the I). Prevalence of ESBL producing bacteria raised in the 
II group in 3 times comparing with the I, though the 
difference was not statistically significant 
(р=0,126).Evaluation of IC causative agents’ susceptibility 
was made for 21 antibiotics in the I group and for 26 in the 
II group(Table 4). 
 
Table 1: Samples with different number of causative agents 
obtained from patients with IC,% 
Number of microorganisms in the sample I group II group p 
1 81,5 52,6 0,020 
2 11,1 15,8 0,724 
3 7,4 23,7 0,105 
 4 0,0 2,6 1,0 
Table 4: IC causative agents’ susceptibility to antibiotics,% 5 0,0 5,3 0,507 
Antibiotic I group II group p 
Total 100,0 100,0 - 
n Susceptibility n Susceptibility 
 
Penicillin 6 16,7 11 45,5 0,350 
The most common causative agent in the I group was 
Pseudomonas aeruginosae (32,4%), though its prevalence 
decreased down to 13,9% in the II group (difference 
statistically significant, p=0,037). Klebsiella pneumoniae 
was the most frequent microorganism in the II group 
(25,0%), but in the I group it was rather more uncommon – 
2,9% only (difference statistically significant, p=0,006). This 
bacteria with Staphylococcus aureus and Enterobacter spp. 
were the most rare microorganisms in the I group. In the II 
group the less common causative agents were 
Stenotrophomonas maltophilia, Serratia marcescens and 
Alcaligenes spp. (1,4% for each), meanwhile in the I group 
none of them was detected. Fungi (Candida spp.) were 
found only in the II group in small amount (2,8%). There 
was no strains of Staphylococcus aureus isolated in the II 
group, though it was present in the I group (Table.2).  
Ampicillin 13 30,8 37 20,3 0,600 
Ampicillin/sulbactam n/d n/d 19 10,5 - 
Amoxicillin/clavulanic 
acid 
n/d n/d 25 0,0 - 
Piperacillin n/d n/d 12 12,5 - 
Piperacillin/tazobactam 3 0,0 24 20,8 0,583 
Ticarcillin/clavulanic 
acid 
n/d n/d 19 21,1 - 
Cefuroxime 4 0,0 17 0,0 1,0 
Cefotaxime 2 50,0 9 0,0 0,327 
Ceftriaxone 3 0,0 27 14,8 0,695 
Cefoperazone 6 25,0 n/d n/d - 
Cefoperazone/sulbacta
m 
4 25,0 24 81,3 0,015 
Ceftazidime 20 10,0 50 9,0 0,995 
Cefepime 16 0,0 49 5,1 0,635 
Imipenem 8 0,0 38 5,3 0,831 
Meropenem 17 35,3 50 31,0 0,814 
Ciprofloxacin 11 22,7 46 8,7 0,373 
Levofloxacin 16 0,0 34 16,2 0,327 
 Amikacin 18 11,1 47 36,2 0,096 
Table 2: Prevalence of IC causative agents in patients with AP,% Gentamicin 33 34,8 58 21,6 0,276 
Causative agent I group II group p Tobramycin 18 27,8 41 56,1 0,085 
Staphylococcus aureus 2,9 0,0 0,321 Vancomycin 8 100,0 16 100,0 1,0 
Staphylococcus spp. 14,7 6,9 0,285 
Tigecycline 13 84,6 8 100,0 0,595 
Streptococcus spp. 5,9 5,6 1,0 
Aztreonam n/d n/d 9 27,8 - 
Enterococcus spp. 17,6 9,7 0,341 
Clindamycin  n/d n/d 8 37,5 - Pseudomonas aeruginosae 32,4 13,9 0,037 
Linezolid 8 100,0 7 100,0 1,0 Stenotrophomonas maltophilia 0,0 1,4 1,0 
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Chloramphenicol 10 65,0 19 36,8 0,211 Causative agents of IC in patients with AP are in majority 
microorganisms, which are resistant to several antibiotics. 
This characteristic of microorganisms does not depend on 
type of drug, which is used for prophylactic antibiotic 
administration during early stages of AP clinical course. 
Note: «n/d» - susceptibility to antibiotic was not tested in this group; 
n – number of bacterial samples tested for susceptibility 
Microorganisms in the I group showed 100% 
susceptibility to vancomycin and linezolid. The majority of 
causative agents also was susceptible to tigecycline (84,6%). 
Bacteria’s resistance in 50% and less percent was detected 
for 5 drugs from 21 (23,8%). Cefotaxime was the only broad 
spectrum antibiotic in abovementioned list (susceptibility of 
50,0%). Total resistance was detected for 6 drugs (28,6%) 
including imipenem, cefepime, and piperacillin/tazobactam. 
For 10 (47,6%) antibiotics bacterial susceptibility varied 
from 10,0-35,3% (including meropenem – 35,3%).  
The increase of ESBL producing bacteria, Gram-negative 
bacteria and microorganisms’ associations among IC 
causative agents is observed.  
Administration of antibiotics from reserve group in case of 
IC occurrence is recommended. 
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